QurAlis
QurAlis's Overview
QurAlis is a clinical-stage biotechnology company at the forefront of developing precision medicines for devastating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Leveraging proprietary human stem cell-based technology platforms and a deep understanding of disease pathology, QurAlis aims to unravel disease complexity and translate scientific discoveries into clinically meaningful therapies. Their pipeline includes novel candidates targeting specific disease-causing mechanisms, with the ultimate goal of transforming the lives of patients and their families.
Where is QurAlis's Headquarters?
HQ Function
The headquarters serves as the central hub for QurAlis's operations, including executive leadership, research and development laboratories, clinical trial management, and business development activities.
Notable Features:
Located within a modern life sciences campus, the facility likely features state-of-the-art laboratory infrastructure, collaborative workspaces, and amenities designed to support cutting-edge scientific research and a dynamic workforce.
Work Culture:
QurAlis fosters a highly collaborative, science-driven, and patient-centric work culture. The environment encourages innovation, rigorous scientific inquiry, and a shared commitment to addressing the urgent unmet needs in neurodegenerative diseases.
HQ Significance:
The Cambridge location provides QurAlis with unparalleled access to a rich ecosystem of academic institutions, research organizations, skilled talent, and potential industry partners, which is critical for accelerating therapeutic development.
Values Reflected in HQ: The choice of a modern facility in a premier biotech hub underscores QurAlis's commitment to scientific excellence, innovation, collaboration, and attracting top-tier talent to achieve its mission.
Location:
While QurAlis is headquartered in the United States, its impact and operations extend globally. The company collaborates with international research institutions, investigators, and clinical trial sites to advance its therapeutic programs. This global approach is essential for developing medicines for neurodegenerative diseases that affect patients worldwide, enabling diverse patient recruitment for clinical studies and access to global expertise.
Street Address:
35 CambridgePark Drive, Suite 400
City:
Cambridge
State/Province:
MA
Country:
USA
QurAlis's Global Presence
Not Publicly Listed
Address: N/A
N/A
Buying Intent Signals for QurAlis
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of QurAlis
As of April 2025, QurAlis' leadership includes:
Investors of QurAlis
QurAlis has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
In the past 12 months, QurAlis notably strengthened its leadership team with the strategic appointment of a new Chief Financial Officer to support its growth and clinical advancement. There have been no publicly announced executive departures during this period.
Departures
New Appointments:
Technology (Tech Stack) used by QurAlis
Discover the tools QurAlis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
QurAlis Email Formats and Examples
QurAlis likely uses standard professional email formats common in the biotechnology industry. Based on available data and common patterns, the most probable formats are [first_initial][last_name]@quralis.com (e.g., jdoe@quralis.com) or [first_name].[last_name]@quralis.com (e.g., jane.doe@quralis.com).
[first_initial][last]@quralis.com
Format
jdoe@quralis.com
Example
70%
Success rate
News and media
QurAlis Press Release • March 5, 2024
QurAlis Appoints Ronen Eyal as Chief Financial Officer
QurAlis announced the appointment of Ronen Eyal as its new Chief Financial Officer. Mr. Eyal brings over 20 years of experience in financial leadership within the biopharmaceutical industry to guide QurAlis's financial strategy as it advances its pipeline....more
QurAlis Press Release • August 23, 2023
QurAlis Announces $88 Million Series B Financing to Advance ALS and FTD Precision Medicines
QurAlis successfully closed an $88 million Series B financing round. The funding was co-led by EQT Life Sciences and Droia Ventures, with significant participation from new and existing investors, to advance its clinical programs QRL-201 for ALS and QRL-101 for FTD, and expand its pipeline....more
QurAlis Press Release • May 16, 2023
QurAlis Announces FDA Orphan Drug Designation Granted to QRL-201 for the Treatment of ALS
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to QurAlis's lead product candidate, QRL-201, for the treatment of amyotrophic lateral sclerosis (ALS). QRL-201 aims to restore STATHMIN-2 (STMN2) function....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including QurAlis, are just a search away.